VOL. XCIV, NO. 247
★ WIDE MOAT STOCKS COMPARISON ★
NO ADVICE
Tuesday, December 30, 2025
Stock Comparison
Wuliangye Yibin Co., Ltd. vs Novo Nordisk A/S
Compare moat strength, market structure, and segment coverage to understand how each company defends its edge.
Wuliangye Yibin Co., Ltd.
000858 · Shenzhen Stock Exchange
Weighted average of segment moat scores, combining moat strength, durability, confidence, market structure, pricing power, and market share.
Full stock profile
Dive deeper into Wuliangye Yibin Co., Ltd.'s moat claims, evidence, and risks.
View 000858 analysisNovo Nordisk A/S
NOVOB · Nasdaq Copenhagen
Weighted average of segment moat scores, combining moat strength, durability, confidence, market structure, pricing power, and market share.
Full stock profile
Dive deeper into Novo Nordisk A/S's moat claims, evidence, and risks.
View NOVOB analysisComparison highlights
- Moat score gap: Novo Nordisk A/S leads (85 / 100 vs 80 / 100 for Wuliangye Yibin Co., Ltd.).
- Segment focus: Wuliangye Yibin Co., Ltd. has 3 segments (76.1% in Wuliangye-branded Baijiu products); Novo Nordisk A/S has 3 segments (71.1% in Diabetes care).
- Primary market structure: Oligopoly vs Oligopoly. Pricing power: Strong vs Moderate.
- Moat breadth: Wuliangye Yibin Co., Ltd. has 5 moat types across 3 domains; Novo Nordisk A/S has 5 across 3.
Primary market context
Wuliangye Yibin Co., Ltd.
Wuliangye-branded Baijiu products
China baijiu market (sales revenue; producers above designated size)
China
Consumers (premium gifting/banqueting; affluent households)
Branded spirits producer and marketer
76.1%
Novo Nordisk A/S
Diabetes care
Diabetes pharmaceuticals (GLP-1 for type 2 diabetes, insulin, and related therapies)
Global
Payers/providers and patients (via wholesalers/pharmacies/hospitals)
Originator pharma (R&D, regulatory, manufacturing, commercialization)
71.1%
Side-by-side metrics
Moat coverage
Shared moat types
Wuliangye Yibin Co., Ltd. strengths
Novo Nordisk A/S strengths
Segment mix
Wuliangye Yibin Co., Ltd. segments
Full profile >Wuliangye-branded Baijiu products
Oligopoly
Other liquor products (Wuliang NongXiang and other series)
Competitive
Non-liquor products (other)
Competitive
Novo Nordisk A/S segments
Full profile >Diabetes care
Oligopoly
Obesity care
Duopoly
Rare disease
Oligopoly
Want the full wide moat stocks list?
Browse the full ranking of wide moat stocks, updated with moat scores and segment context.
View the moat stocks listCuration & Accuracy
This directory blends AI‑assisted discovery with human curation. Entries are reviewed, edited, and organized with the goal of expanding coverage and sharpening quality over time. Your feedback helps steer improvements (because no single human can capture everything all at once).
Details change. Pricing, features, and availability may be incomplete or out of date. Treat listings as a starting point and verify on the provider’s site before making decisions. If you spot an error or a gap, send a quick note and I’ll adjust.